Dose compounded tirzepatide

Compounded tirzepatide is no longer broadly available in the U.S. following the FDA's declaration that the shortage of the brand-name drugs Mounjaro and Zepbound has ended. It can only be legally obtained in rare cases of specific medical necessity, and its use carries significant safety risks compared to the FDA-approved versions.

The legal landscape for compounded tirzepatide changed dramatically in late 2024. Due to high demand, the FDA added tirzepatide to its drug shortage list in December 2022, which temporarily allowed pharmacies to compound it. However, the FDA determined that the shortage was resolved in October 2024 and upheld this decision in December 2024.

As of early 2026, broad-scale compounding is no longer permitted. The grace periods for pharmacies to stop production have passed, meaning compounding pharmacies can no longer regularly make tirzepatide. The only exceptions are for individual patients with a specific medical need, such as a documented allergy to an ingredient in the FDA-approved drug.

It's crucial to understand that compounded tirzepatide is not FDA-approved. This distinction carries important implications for your safety and treatment.

• No FDA Approval: The FDA does not verify the safety, effectiveness, or quality of compounded drugs. This means there is no guarantee that the product contains the correct amount of medication, is sterile, or is free from harmful contaminants.
• Variable Quality and Ingredients: The strength, inactive ingredients, and formulation of compounded tirzepatide can vary between pharmacies. Some products may be made with unauthorized forms of tirzepatide or mixed with other substances like vitamins, the safety of which has not been established for this use.
• Real-World Data: A 2025 study published in the Journal of the American College of Clinical Pharmacy showed that during the shortage, patients using compounded tirzepatide under pharmacist supervision experienced significant weight loss and improved cardiometabolic outcomes. However, this was within a carefully managed clinical setting and does not guarantee similar results from any unverified source.
• Reported Side Effects: The known side effects of tirzepatide (nausea, vomiting, diarrhea, constipation, abdominal pain) are also associated with compounded versions. However, due to quality control issues, the risks of experiencing these side effects, potentially in a more severe form, may be higher.

The FDA has signaled that enforcing rules around compounded GLP-1 drugs is a priority.

• End of Shortage: The FDA's decision to remove tirzepatide from the shortage list was the primary trigger for ending broad compounding.
• Legal Challenges: A lawsuit filed by the compounding industry challenged the FDA's decision. In March 2026, the FDA agreed to reconsider its ruling, putting the case on hold. While this means the agency is taking a second look, the current legal status remains that the shortage is resolved, and the official FDA ruling on the matter is still in place.
• Enforcement: In March 2026, the FDA sent warning letters to telehealth companies for making misleading claims about their compounded GLP-1 products, signaling that the agency is actively monitoring and enforcing regulations in this area.

If you are currently using a compounded version or are thinking about it, here are your safest steps forward:

1. Talk to Your Doctor: This is the most important step. Discuss whether you have a valid medical necessity that would legally permit compounding (like an allergy) or if you should transition to a branded option. Do not stop or change your medication without medical guidance.
2. Verify the Pharmacy: If your doctor determines compounding is medically necessary, only use a state-licensed pharmacy or an FDA-registered outsourcing facility (503B). You can verify a pharmacy's credentials with your state's Board of Pharmacy.
3. Check for Legitimacy: A safe product will come with a clear lot number and a "beyond-use date" (BUD). Avoid any pharmacy selling "research grade" tirzepatide, products without a prescription, or those using salt forms like "tirzepatate sodium," which are not approved for human use.

The two FDA-approved brand-name versions of tirzepatide, which have undergone rigorous testing for safety and efficacy, are:

• Brand Name Primary FDA-Approved Use
• Mounjaro® Type 2 Diabetes (to improve blood sugar control)
• Zepbound® Chronic Weight Management (obesity/overweight) and Moderate-to-Severe Obstructive Sleep Apnea

Both contain the exact same active ingredient and are available in pre-filled pens or vials. For those with insurance coverage for either diabetes or weight loss, these are the safest options.